中生方政NBF品牌怎么样 申请店铺

我要投票 中生方政NBF在医疗器械行业中的票数:206 更新时间:2025-04-27
中生方政NBF是哪个国家的品牌?「中生方政NBF」是 中生方政生物技术股份有限公司 旗下著名品牌。该品牌发源于江苏省泰州市,由创始人郭光华在2009-09-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生方政NBF品牌出海!通过在本页面挂载中生方政NBF品牌的产品链接和联系方式,可以提高中生方政NBF产品曝光!跨境电商爆单神器,目前只要100元/年哦~

中生方政NBF怎么样

中生方政生物技术股份有限公司,成立于2009年,是一家集诊断试剂、生物医药、预防性疫苗及仪器设备的研发和生产为一体的生物医药技术企业。占地面积近55000平方米,建筑面积25700 平方米。研发总部设立在美国,主要从事具有国际前沿技术水平的体外诊断试剂的开发和研制。已建成核酸分子诊断试剂生产车间、金标车间、酶联免疫诊断试剂生产车间、中试(设备)车间、动力中心、动物实验楼、综合楼(研发中心)等标准化GMP生产车间及现代化办公配套设施,现已完成规模化产业基地的建设,形成了年产分子诊断试剂1000万人份和分子检测设备1000台的生产能力。

中生方政长期专注于临床分子诊断技术的开发。在国内IVD行业,中生方政是为数不多拥6项以上注册文号的生产企业,实现了产品价格多层次化,产品结构梯队化,可以满足不同客户的检测需求和价格承受能力,具有较宽的市场辐射面,为市场纵深开发打下了良好基础。

作为前沿技术创新主导型高科技企业,公司依托自主研发及联合开发等多种方式,创建了成熟稳定的新型核酸检测技术平台,并已先期开发出人乳头瘤病毒(HPV)临床检测试剂,成为国内首个利用恒温技术检测HPV病毒的产品。目前公司已获得国家食品药品监督总局颁发的15种型别人乳头瘤病毒和16/18型人乳头瘤病毒核酸检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)基因分型检测试剂盒(恒温扩增-荧光法)、人乳头瘤病毒(HPV)核酸检测试剂盒(恒温扩增-荧光法)等产品注册证书。同时,公司还开发出配套的恒温荧光检测设备。依托于该技术平台,公司正在努力拓展产品线,逐步推进试剂和仪器的“系列化”、“一体化”发展目标。

中生方政将本着“用心、专注、创新、服务”的企业理念和“成为国内在体外诊断试剂产业领域最具创新研发能力的优秀产品与服务供应商”的发展愿景,“资本加创新”双轮驱动的发展战略,以及“质量第一 追求卓越”的管理理念,愿同社会各界合作共赢,回馈股东、客户和员工,进而为推动我国医学检验产业及健康医疗事业的发展做出新的贡献。


Zhongsheng Fangzheng Biotechnology Co., Ltd., founded in 2009, is a biomedical technology enterprise integrating research and development and production of diagnostic reagents, biomedicine, preventive vaccines and equipment. It covers an area of nearly 55000 square meters and a building area of 25700 square meters. R & D headquarters is established in the United States, mainly engaged in the development and development of in vitro diagnostic reagents with international cutting-edge technology level. Standardized GMP production workshops and modern office facilities have been built, such as nucleic acid molecular diagnostic reagent production workshop, gold standard workshop, enzyme-linked immunodiagnostic reagent production workshop, pilot test (equipment) workshop, power center, animal laboratory building, comprehensive building (R & D center). The construction of large-scale industrial base has been completed, with an annual output of 10 million people and molecules of molecular diagnostic reagents Production capacity of 1000 testing equipment. Zhongsheng Fangzheng has long focused on the development of clinical molecular diagnosis technology. In the domestic IVD industry, Zhongsheng Fangzheng is one of the few manufacturers with more than 6 registered numbers. It has realized multi-level product price and echelon product structure, which can meet the testing needs and price tolerance of different customers. It has a wide market radiation and lays a good foundation for in-depth market development. As a leading high-tech enterprise of cutting-edge technology innovation, the company has established a mature and stable new nucleic acid detection technology platform relying on independent research and development and joint development, and has developed the clinical detection reagent of human papillomavirus (HPV) in advance, becoming the first domestic product using constant temperature technology to detect HPV virus. At present, the company has obtained product registration certificates issued by the State Food and drug administration, such as 15 types of HPV and 16 / 18 HPV nucleic acid detection kits (constant temperature amplification fluorescence method), HPV gene typing detection kits (constant temperature amplification fluorescence method), HPV nucleic acid detection kits (constant temperature amplification fluorescence method), etc Book. At the same time, the company also developed a complete set of constant temperature fluorescence detection equipment. Relying on this technology platform, the company is striving to expand its product line and gradually promote the development goals of "serialization" and "integration" of reagents and instruments. Zhongsheng Fangzheng is willing to cooperate with all walks of life for win-win cooperation and feedback with the corporate philosophy of "heart, focus, innovation and service", the development vision of "becoming the best product and service provider with the most innovative R & D ability in the field of in vitro diagnostic reagent industry in China", the development strategy of "capital plus innovation" driven by two wheels, and the management concept of "quality first pursuit of excellence" Shareholders, customers and employees will make new contributions to the development of China's medical testing industry and health care industry.

本文链接: https://brand.waitui.com/2c7dece2d.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美团:“因使用双开或京东软件,被永久停止接单”系恶意P图造谣

4月27日,美团发布声明称,在澄清“去其他平台跑单会被美团永久封号”的谣言后,社交平台上依旧出现了骑手App显示“永久停止接单原因为:存在使用双开或京东软件的行为”的谣言图片。经核实,该图片源自平台封禁违规抢单外挂的正常提示页,但ip地址在广东的个别网民,对图片进行恶意P图后,极少数网民在微信群内进行传播。目前公司已针对谣言传播情况进行证据固定,将通过法律手段维护自身权益。对于恶意发布上述不实图片,持续散播谣言的虚假摆拍账号、幕后推手,公司也会加大固证和打击力度。(界面新闻)

2小时前

万事网联推出支付标记化服务

36氪获悉,4月25日,万事网联正式推出支付标记化服务。支付标记化服务,即应用支付标记化技术(Tokenization),替代银行卡卡号、卡片验证码、支付机构支付账户等敏感信息,并通过设置支付标记的交易次数、交易金额、有效期和支付渠道等约束规则,从源头控制信息泄露和欺诈交易风险。通过这项服务,交易全程无须出现银行卡卡号、有效期等关键信息,持卡人可以实现在数字钱包或超级应用上的无卡支付,还可以绑定智能手机、可穿戴设备在线下使用,在保障安全的同时提升支付便利性。

2小时前

许晓征任深圳金融监管局副局长

36氪获悉,4月27日,国家金融监督管理总局深圳监管局网站“局领导”栏目更新显示,许晓征任国家金融监督管理总局深圳监管局党委委员、副局长。

2小时前

纳芯微汽车芯片累计出货6.68亿颗

36氪获悉,近日,纳芯微亮相2025年上海国际车展5.2馆“中国芯”展区。据介绍,截止2024年,纳芯微汽车芯片累计出货量达6.68亿颗,仅在新能源汽车三电系统领域,纳芯微已为近400家零部件供应商建立深度合作,为主驱逆变器、车载充电机(OBC)、电池管理系统(BMS)等领域提供完整的芯片解决方案。

2小时前

苏州恒道餐饮管理有限公司完成1200万元A轮融资

36氪获悉,近日,苏州恒道餐饮管理有限公司旗下品牌“福来魏”完成1200万元A轮融资,本轮由上海潮信实业投资有限公司投资。此次融资将主要用于供应链体系升级、数字化系统建设及全国市场拓展。福来魏创立于2017年,以陕西凉皮、肉夹馍、油泼面三大爆款为核心,延伸出30余款高复购率产品矩阵。

2小时前

本页详细列出关于中生方政NBF的品牌信息,含品牌所属公司介绍,中生方政NBF所处行业的品牌地位及优势。
咨询